Cytotherapy Editorial Board

Cytotherapy CoverMission Statement

To be the premier cell and gene therapy translation journal.

Aims and Scope

Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. In addition to Short Reports and Full-Length Articles, the journal also accepts Editorials on emerging trends and potential controversies in the field, and Review articles summarizing important areas of cell and gene therapy research that are topical and/or challenge existing paradigms in the field.

Cytotherapy considers manuscripts exploring the following topics:

  • Development and/or characterization of novel gene therapies and cell and/or EV-based therapeutics.
  • Design of novel therapeutic approaches employing cell/EV/gene products.
  • Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
  • Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.
  • Role of stem/stromal cells and/or EVs in disease pathophysiology.
  • Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.
  • Important advances in cell/EV/gene-based product manufacturing and validation.
  • Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.


Cytotherapy does not publish manuscripts on the following topics:

  • Case studies unless they are of unusual significance to the field.
  • Basic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiology.
  • Studies describing signaling pathways implicated in cancer.

Readership and Target Group

Cytotherapy provides essential reading for scientists, physicians, technicians and regulatory experts involved in cell processing and therapy. It is a vital resource for hematologists, oncologists and immunologists, and the growing number of physicians from many disciplines involved in tissue repair and stem cell research, cytokine investigators, cancer biologists and biotherapists.


Cytotherapy, Cytokine, Translational Research, Stem Cells, Cellular Therapies, Vaccines, Gene Therapy, Immunotherapy, Tissue Engineering, Blood and Bone Marrow, T cells.

Submission Details

Cytotherapy publishes original papers, reviews, novel hypotheses, short communications, book reviews and editorials. Submitted manuscripts will be reviewed by at least two reviewers. Authors will be notified within 30 working days of receipt whether the manuscript is accepted, requires revision or is rejected. All manuscripts will be published within five months from the date of acceptance. Contributors, submit manuscripts here.

Journal Leadership

Edwin Horwitz.jpgEditor-in-Chief

Edwin M. Horwitz, MD, PhD

Emory University School of Medicine
United States

Patrick_Hanley_2017_cropped.jpgCommissioning Editor

Patrick J. Hanley, PhD

Children's National Hospital
United States

Associate Editors

Oscar Lee, MD, PhD
National Yang-Ming University

Susan E. Prockop, MD
Boston Children's Hospital

United States
Anna Pasetto, PhD
Karolinska Institutet

Qasim A. Rafiq, PhD
University College London

United Kingdom
Sowmya Viswanathan, PhD
University Health Network


Assistant Editor

Rachel A. Burga, PhD
Obsidian Therapeutics
United States

Editorial Board

The editors are supported by an international editorial board made up of over 35 eminent academics in the field.


Ande Nichols
Publisher, Cytotherapy